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Abstract. 
 
Integrin-associated protein (IAP/CD47) aug-
ments the function of 
 
a
 
2
 
b
 
1 integrin in smooth muscle 
cells (SMC), resulting in enhanced chemotaxis toward 
soluble collagen (Wang, X-Q., and W.A. Frazier. 1998. 
 
Mol. Biol. Cell.
 
 9:865). IAP-deﬁcient SMC derived 
 
from IAP
 
2/2
 
 animals did not migrate in response to 
4N1K (KRFYVVMWKK), a peptide agonist of IAP 
derived from the COOH-terminal domain of thrombo-
spondin-1 (TSP1). When normal SMC were preincu-
bated with 4N1K or an anti-
 
a
 
2
 
b
 
1 function-stimulating 
antibody, cell migration to soluble collagen was signiﬁ-
cantly enhanced. 4N1K-induced chemotaxis was 
blocked by treatment of SMC with pertussis toxin indi-
cating that IAP acts through Gi. In agreement with this, 
4N1K evoked a rapid decrease in cAMP levels which 
was intensiﬁed in the presence of collagen, and forsko-
lin and 8-Br-cAMP both inhibited SMC migration stim-
ulated via IAP. 4N1K strongly inhibited extracellular 
regulated kinase (ERK) activation in SMC attaching to 
collagen and reduced basal ERK activity in suspended 
SMC. Pertussis toxin treatment of SMC signiﬁcantly ac-
tivated ERK, suggesting that an inhibitory input was
alleviated. Inhibition of ERK activity by (a) the MAP 
kinase kinase (MEK) inhibitor, PD98059, (b) antisense 
oligonucleotide depletion of ERK, and (c) expression 
of mitogen-activated protein (MAP) kinase phos-
phatase-1 in SMC all led to increased migration to col-
lagen, 4N1K, or 4N1K plus collagen. Thus, IAP stimu-
lates 
 
a
 
2
 
b
 
1 integrin-mediated SMC migration via
Gi-mediated inhibition of ERK activity and suppres-
sion of cyclic AMP levels. Both of these signaling path-
ways could directly modulate the state of the integrin as 
well as impact downstream components of the cell mo-
tility apparatus.
Key words: integrin-associated protein • chemotaxis • 
MAP kinase • heterotrimeric G-proteins • cyclic AMP
 
M
 
IGRATION
 
 of vascular smooth muscle cells (SMC)
 
1
 
is a major contributor to intimal thickening dur-
ing the progression of vascular disease (Cass-
cells, 1992; Ross, 1993). Many potential regulators of SMC
migration have been identified, including chemotactic cy-
tokines and growth factors, as well as extracellular matrix
(ECM) molecules (Dubey et al., 1995; Nelson et al., 1996;
Pickering et al., 1997). Integrins are the major family of
cell surface adhesion receptors that have been implicated
in cell migration (Hynes, 1992; Huttenlocher et al., 1995).
In cultured SMC, migration has been noted to be depen-
dent on 
 
a
 
v
 
b
 
3 integrin (Yue et al., 1994), but a number of
recent studies have also implicated 
 
a
 
2
 
b
 
1 integrin in SMC
migration. For example, platelet-derived growth factor
(PDGF) induced SMC migration on collagen via activa-
tion of 
 
a
 
2
 
b
 
1 integrin (Skinner et al., 1994). Fibroblast
growth factor-2 (FGF-2) upregulated 
 
a
 
2
 
b
 
1 expression and
potentiated SMC migration to PDGF (Pickering et al.,
1997). Further, blockade of 
 
a
 
2
 
b
 
1 function inhibited SMC
migration to collagen (Yue et al., 1994; Wang and Frazier,
1998). Efficient cell migration requires that integrin-medi-
ated interactions between the cell’s surface and the sub-
stratum be dynamically regulated to allow a cell to
progress over its substratum (Dimilla et al., 1991; Lauffen-
burger and Horwitz, 1996). Directed cell migration, be it
haptotaxis or chemotaxis, requires that another layer of
 
Address correspondence to William A. Frazier, Department of Biochem-
istry and Molecular Biophysics, Box 8231, Washington University School
of Medicine, St. Louis, MO 63110. Tel.: (314) 362-3348. Fax: (314) 362-
7183. E-mail: frazier@biochem.wustl.edu
 
1.
 
 Abbreviations used in this paper: 
 
4N1K, KRFYVVMWKK; 4NGG,
KRFYGGMWKK; cAMP, 3
 
9
 
-5
 
9
 
 cyclic adenosine monophosphate; ECM,
extracellular matrix; ERK, extracellular regulated kinase (MAP kinase
p42/p44); FGF-2, fibroblast growth factor-2; IAP, integrin-associated pro-
tein or CD47; MAP, mitogen-activated protein; MEK, MAP kinase ki-
nase; MKP-1, MAP kinase phosphatase 1; PDGF, platelet-derived growth
factor; SMC, smooth muscle cells; TSP, thrombospondins (TSP1, platelet
thrombospondin). 
The Journal of Cell Biology, Volume 147, 1999 390
 
sensory inputs take control of the basic mechanisms that
generate cell motility. This regulation of integrin function
is particularly difficult to understand in terms of our cur-
rent views of cell adhesion. Clearly, changes in affinity or
avidity of integrins must occur during cell migration, which
very likely depend on rapid, controlled modulation of in-
side out signaling (Hynes, 1992; Shattil et al., 1994; Hughes
and Pfaff, 1998).
The classic example of integrin affinity modulation is
the nearly instantaneous transition of platelet 
 
a
 
IIb
 
b
 
3 from
a low affinity/avidity state to a state in which it can effec-
tively bind soluble fibrinogen resulting in rapid platelet ag-
gregation (Shattil et al., 1994, 1998; Chung et al., 1997).
Resting platelets are unable to aggregate because their
 
a
 
IIb
 
b
 
3 is in an inactive conformation that has a low affin-
ity for soluble fibrinogen. However, they can attach quite
well to surfaces coated with fibrinogen (Chung et al., 1997;
Shattil et al., 1998), a situation in which ligand valency
overcomes the inherent low affinity of each receptor. Af-
ter platelet activation by specific agonists, such as throm-
bin and other coactivators that bind to heptahelical or
seven transmembrane segment receptors, inside out sig-
naling causes 
 
a
 
IIb
 
b
 
3 to undergo a conformational change
that dramatically increases its binding affinity and/or avid-
ity for fibrinogen, resulting in platelet aggregation (Shattil
et al., 1998). Unactivated platelets adherent to fibrinogen
cannot spread unless 
 
a
 
IIb
 
b
 
3 is activated by inside out sig-
naling initiated by one of these costimulators (Chung et
al., 1997; Shattil et al., 1998).
We have recently reported that integrin-associated pro-
tein (IAP or CD47) on platelets is also a costimulatory
receptor for 
 
a
 
IIb
 
b
 
3 activation (Chung et al., 1997), and
that the COOH-terminal domain of thrombospondin-1
(TSP1), a ligand for IAP (Gao et al., 1996a,b), initiates the
same signaling pathway leading to 
 
a
 
IIb
 
b
 
3 activation as re-
ceptors for other agents such as thrombin, ADP, and epi-
nephrine. IAP forms a physical complex with certain inte-
grins (Brown et al., 1990; Gao et al., 1996a,b; Wang and
Frazier, 1998), and blockade of IAP with mAbs inhibits
some aspects of integrin signaling (Lindberg et al., 1996).
This data has led to the notion that IAP is involved in out-
side in signaling. However, our recent studies of platelet
activation and spreading and chemotaxis of nucleated cells
indicate that IAP initiates a signaling pathway to upregu-
late integrin function, that is, inside out signaling (Bly-
stone et al., 1995; Gao et al., 1996a; Chung et al., 1997, 1999;
Wang and Frazier, 1998). In platelets, ligation of IAP with
the agonist peptide 4N1K (KRFYVVMWKK), the recom-
binant COOH-terminal domain of TSP1 or TSP1 itself,
initiates a signaling pathway very similar to that of platelet
agonists such as thrombin or epinephrine, resulting in
platelet activation and affinity modulation of 
 
a
 
IIb
 
b
 
3 to al-
low binding of soluble fibrinogen and spreading on a fi-
brinogen substrate (Chung et al., 1997). Endothelial cells
(Gao et al., 1996b) and melanoma cells (Gao et al., 1996a)
migrating on gelatin-coated surfaces are attracted towards
4N1K, and this appears to involve modulation of 
 
a
 
v
 
b
 
3
which these cells use for traction on this RGD-containing
matrix.
Whereas members of the 
 
b
 
1 family of integrins in gen-
eral do not depend on inside out signaling for activation,
 
a
 
4
 
b
 
1 is subject to this sort of rapid modulation or activa-
tion in leukocytes, a process with an essential role in the
pathogenesis of thrombosis, inflammation, and autoim-
mune diseases (Hynes, 1992; Carlos and Harlan, 1994).
The 
 
b
 
1-integrin–mediated adhesion of leukocytes to ECM
proteins can be activated by chemokines (Springer, 1994),
divalent cations (Dobrina et al., 1991), phorbol ester
(Wilkins et al., 1991), cross-linking of cell surface recep-
tors (Shimizu et al., 1991), and certain antibodies to 
 
b
 
1 in-
tegrins (Kovach et al., 1992) without changes in cell sur-
face expression of the integrin. In addition, 
 
a
 
2
 
b
 
1 can exist
in three distinguishable functional states, depending on
the cell type in which it is expressed (Chan and Hemler,
1993; Santoro and Zutter, 1995). When expressed in K562
cells, the 
 
a
 
2
 
b
 
1 integrin is present on the cell surface but
does not allow the cells to bind to either collagen or lami-
nin, two common ligands for 
 
a
 
2
 
b
 
1. When it is expressed
on platelets and some types of fibroblasts, 
 
a
 
2
 
b
 
1 binds col-
lagen, and when expressed on endothelial and many epi-
thelial cells, it binds both collagen and laminin. We have
observed another type of more acute regulation of 
 
a
 
2
 
b
 
1
integrin on cultured aortic SMC in which TSP1 and a pep-
tide derived from its COOH-terminal domain (4N1K) can
modulate the function of 
 
a
 
2
 
b
 
1 such that it more effec-
tively promotes chemotaxis of the cells towards soluble
collagen. This effect on 
 
a
 
2
 
b
 
1 function is mediated by the
cell surface TSP1 receptor IAP (or CD47) (Wang and Fra-
zier, 1998). SMC migrate on gelatin-coated filters using
 
a
 
2
 
b
 
1 for traction and this migration can be directed by
gradients of either soluble collagen (Nelson et al., 1996),
or the IAP agonist peptide 4N1K (Wang and Frazier,
1998). We noted that, when present together, soluble col-
lagen and 4N1K provoke a highly synergistic chemotactic
response (Wang and Frazier, 1998). This enhanced chemo-
taxis requires both 
 
a
 
2
 
b
 
1 and IAP as judged by the effects
of function blocking antibodies. In this report, we investi-
gate the mechanism by which IAP modulates 
 
a
 
2
 
b
 
1-medi-
ated SMC migration. We find that, just as in platelets
(Chung et al., 1999; Frazier et al., 1999), IAP acts via a het-
erotrimeric Gi protein to decrease intracellular cyclic
AMP levels. In addition, ligation of IAP evokes a rapid
and substantial inhibition of mitogen-activated protein
(MAP) kinase (ERKs). Both of these events have been
implicated in modulation of integrins and both also impact
the cell’s motility apparatus downstream of integrin sig-
naling.
 
Materials and Methods
 
Reagents
 
Peptides were synthesized, purified, and confirmed by mass spectrometry
at the Protein and Nucleic Acid Chemistry Laboratory of Washington
University School of Medicine as described previously (Kosfeld and Fra-
zier, 1992; Gao et al., 1996a,b). The amino acid sequences of the TSP1
peptides and preparation of human platelet TSP1 were as described (San-
toro and Frazier, 1987). Rat tail collagen-I was obtained from Collabora-
tive Biochemical Products. The signal transduction inhibitors and activa-
tors were purchased from CalBiochem-Novabiochem. Both anti-
 
a
 
2
 
b
 
1
antibodies (function stimulating, JBS2, and blocking, BHA2.1) were from
Chemicon International. Anti-ERK antibody was from Upstate Biotech-
nology Inc. Anti-active (-phosphorylated) ERK antibody was from
Promega. Anti-ERK polyclonal antibody for Western blotting was from
Santa Cruz Biotechnology, Inc. cAMP enzyme immunoassay (EIA) sys-
tem (dual range) kits and 
 
g
 
-[
 
32
 
P]ATP were from Amersham. Myelin basic 
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protein and anti–mouse IgG agarose were from Sigma Chemical Co. The
plasmids 3CH134 encoding MAP kinase phosphatase 1 (MKP-1) and the
catalytically inactive mutant of MKP-1 were generously provided by Dr.
N. Tonks (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
 
Cell Culture and Transfection
 
Human and mouse aortic SMC were isolated by the explant method and
cultured as described (Ross and Kariya, 1980). Cells were maintained in a
humidified 37
 
8
 
C and 5% CO
 
2
 
 environment in MEM with 20% fetal calf
serum, and identified by immunostaining of 
 
a
 
-actin (Janat and Liau,
1992). Passages 2–10 were used for experiments. Cell transfection using
Lipofectamine was as described (Sun et al., 1993). In brief, cells at 50–60%
confluence were transiently transfected with 20 
 
m
 
g cDNA of each plasmid
for 5 h, and recovered in growth medium for 2 d before they were har-
vested, tested for viability, and counted for use in assays.
 
Treatment of Cells with Anti-Sense
ERK Oligonucleotides
 
Depletion of ERK from cells was performed according to the procedure
of Klemke et al. (1997). In brief, SMC grown to 60% confluence in 100-mm
tissue culture dishes were incubated in Opti-MEM medium (GIBCO
BRL) containing Lipofectamine (10 
 
m
 
g/ml) and 1.5 
 
m
 
M ERK antisense
(5
 
9
 
-GCC GCC GCC GCC GCC AT-3
 
9
 
) or control (5
 
9
 
-CGC GCG CTC
GCG CAC CC-3
 
9
 
) phosphorothioate oligonucleotides for 5 h at 37
 
8
 
C.
Cells were then rinsed, incubated for 2 d in fresh culture medium contain-
ing oligonucleotide, and then tested in migration assays as described
above and processed for Western blotting with anti-ERK antibody.
 
Cell Migration
 
Chemotaxis assays were conducted in 48-well micro-Boyden chambers
(Neuroprobe) using 8-
 
m
 
m PVP-free, polycarbonate filters (Nucleopore).
Filters were precoated by soaking in 100 
 
m
 
g/ml gelatin at 37
 
8
 
C overnight,
followed by washing twice in PBS. SMC were harvested with trypsin/
EDTA, washed, and diluted in MEM with 0.1% BSA to a final concentra-
tion of 3–5 
 
3 
 
10
 
5 
 
cells/ml. Chemoattractants were diluted in the same solu-
tion. Signal transduction inhibitors or activators were added to the cell
suspension directly at the concentration indicated. The assembled cham-
ber was incubated for 6 h at 37
 
8
 
C. Filters were fixed, stained, and
mounted. Cells were counted in five high-power fields (HPF) in each of
the triplicate wells for each condition.
 
ERK Assays
 
Immune Complex ERK Assay. 
 
Human SMC were harvested by EDTA/
trypsin. After challenging with different treatments, either on matrix pro-
tein-coated 35-mm dishes or in suspension for indicated times, SMC were
lysed directly at 4
 
8
 
C for 30 min in RIPA buffer including phosphatase in-
hibitors (50 mM Tris, pH 7.4, 0.15 M NaCl, 1% NP-40, 0.5% sodium de-
oxycholate, 1 mM EGTA, 1 mM Na
 
3
 
VO
 
4
 
, and 20 mM 
 
b
 
-glycerophosphate)
and protease inhibitors (10 
 
m
 
g/ml each of antipain, pepstatin A, chymosta-
tin, leupeptin, soybean trypsin inhibitor, and aprotinin). The clarified cell
lysates were incubated with 3 
 
m
 
g/tube of anti-MAP kinase antibody over-
night at 4
 
8
 
C and then immunoprecipitated with anti–mouse IgG agarose
for 1 h at 4
 
8
 
C. The precipitates were extensively washed with 1:3 diluted
RIPA buffer three times and then two times with PBS. The immune com-
plexes were resuspended in 60 
 
m
 
l kinase assay buffer (20 mM Hepes, pH
7.4, 1 mM EGTA, 20 mM 
 
b
 
-glycerophosphate, 0.1 mM Na
 
3
 
VO
 
4
 
, 1 mM
dithiothreitol, and 10 mM MgCl
 
2
 
) including 20 
 
m
 
g myelin basic protein, 50
 
m
 
M ATP and 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP, and incubated at 30
 
8
 
C for 30 min. The re-
action was stopped by adding 20 
 
m
 
l of 100 mM EDTA (pH 7.0). After cen-
trifugation to pellet the beads, aliquots (20 
 
m
 
l) of the supernatants were
spotted onto P81 filters (Sevetson et al., 1993). The filters were washed 10
times with 1% phosphoric acid and then rinsed with 90% ethanol. The
amount of 
 
32
 
P incorporated into myelin basic protein was determined by
scintillation counting.
 
Western Blotting of ERKs. 
 
Human SMC were treated as described
above and lysed in RIPA buffer. Clarified cell lysates (50 
 
m
 
l) were added
to 2
 
3
 
 SDS-sample buffer and run on 12% Tris-glycine gels under reduc-
ing conditions. The proteins were transferred electrophoretically onto ni-
trocellulose membranes which were blocked with 3% BSA plus 3% dried
milk in TBS buffer with 0.1% Tween-20 for at least 1 h, and subsequently
incubated with antibody against ERKs overnight at 4
 
8
 
C. The membranes
 
were washed extensively and incubated with peroxidase-conjugated sec-
ondary antibody for 1 h. Detection was by chemiluminescence with an
ECL kit (Amersham).
 
Measurement of Cyclic AMP
 
Human SMC were harvested with EDTA/trypsin, resuspended in serum-
free MEM at 2.5 
 
3 105/ml, and incubated with peptides or inhibitors for
the indicated times. Cells were pelleted and cAMP was rapidly extracted
twice with the addition of 100 ml of ice-cold ethanol (70%) for 30 min. Su-
pernatants were collected and evaporated in a SpeedVac. The samples
were dissolved in 5 ml assay buffer. The levels of cAMP were determined
using a cAMP enzyme immunoassay system kit from Amersham.
Results
4N1K Stimulation of Chemotaxis Requires IAP
We previously found that either soluble type I collagen
or the TSP1 peptide 4N1K alone are relatively weak
chemoattractants of human aortic SMC migrating on a
matrix of gelatin. However, in combination they provoke a
strong chemotactic response. This response is, in fact,
chemotactic (not chemokinetic) and depends on the func-
tion of both a2b1 and IAP (Wang and Frazier, 1998). To
determine if the a2b1 integrin-dependent migration of
SMC stimulated by 4N1K is strictly dependent on IAP, we
examined the response of IAP-deficient SMC isolated
from aortae of IAP2/2 mice (Lindberg et al., 1996). As
shown in Fig. 1, both 4N1K and collagen can induce migra-
tion of wild-type SMC (IAP1/1), and 4N1K plus soluble
collagen together provoke a strong response, z200% com-
pared with control cells, similar to the response of human
SMC (Wang and Frazier, 1998). However, 4N1K does not
induce migration of IAP-deficient SMC. When soluble
collagen is added along with 4N1K, the level of response is
equal to the effect of collagen alone (Fig. 1) which reflects
the action of a2b1 in the unstimulated state (Wang and
Frazier, 1998). This response to collagen also indicates that
there is no significant defect in the ability of the IAP2/2
SMC to adhere to collagen. This was confirmed in quanti-
tative cell adhesion assays (not shown). Thus, 4N1K stimu-
lation of chemotaxis with or without soluble collagen is re-
ceptor mediated and is strictly dependent on the presence
of IAP. This also rules out a number of trivial explanations
Figure 1. IAP is necessary
for stimulation of chemo-
taxis by 4N1K. SMC from
both IAP1/1 and IAP2/2 mice
were tested for chemotactic
migration when stimulated
with 5 mg/ml collagen (Col),
100 mM 4N1K, or 100 mM
4N1K plus 5 mg/ml collagen-I
(4N1K1Col). SMC were al-
lowed to migrate through
gelatin-coated filters toward
attractants placed in the bot-
tom wells of the micro-Boy-
den chamber. After staining, cells were counted in five high
power fields in each of triplicate wells. Data is expressed as the
percentage increased migration relative to control wells with no
attractant to control for random motility. Error bars indicate
standard deviation.The Journal of Cell Biology, Volume 147, 1999 392
(e.g., aggregation of collagen) for the enhanced chemo-
taxis.
Pretreatment with 4N1K Activates Chemotaxis
Our previous work suggested the hypothesis that IAP
stimulates  a2b1 integrin function in SMC by activating the
integrin in some way (Chung et al., 1997, 1999; Wang and
Frazier, 1998). If this is in fact the case, 4N1K may not
need to be present during the chemotaxis assay and pre-
treatment of SMC with 4N1K might sensitize the cells to
respond better to a gradient of soluble collagen. Thus, we
compared the effects of pretreatment of SMC with 4N1K
and with an anti-a2b1 mAb known to activate the integrin
on other cell types (Arroyo et al., 1993; Chan and Hemler,
1993; Stupack et al., 1994). As shown in Fig. 2, cells pre-
treated with 4N1K for 30 min and washed before placing
them into the chemotaxis apparatus displayed significantly
increased migration to soluble collagen. Pretreatment with
the control peptide 4NGG (KRFYGGMWKK) had no ef-
fect. This effect of 4N1K is not due to residual bound pep-
tide since direct binding assays using 125I-4N1K reveal a
very fast off rate (Dimitry, J.B., and W.A. Frazier, unpub-
lished data). Similar results to those with 4N1K were ob-
served when the cells were preincubated with the a2b1
function stimulating antibody: the migration to collagen
increased more than threefold in three experiments (Fig.
2). An a2b1 functional blocking mAb was tested in the
same experiment, and it effectively inhibited cell migra-
tion (Wang and Frazier, 1998). These data support the no-
tion that ligation of IAP activates a2b1 for a period of
time and it is this activation of a2b1 that is responsible for
the enhanced migration of SMC towards soluble collagen
(Pickering et al., 1997; Wang and Frazier, 1998).
Effect of IAP Stimulation on Adhesion of SMC
Chemotaxis is complex process in which cell adhesion and
deadhesion are regulated in a dynamic way (Lauffen-
burger and Horwitz, 1996). In an attempt to assess the ef-
fects of 4N1K stimulation of IAP on a more direct index of
integrin function, we tested the effect of 4N1K on the ad-
hesion of SMC to gelatin and collagen-coated surfaces. As
expected, collagen is a much better ligand for a2b1 than
gelatin (Fig. 3). These SMC adhere to both collagen and
gelatin via a2b1 as determined with a function-blocking
mAb (not shown). For both immobilized ligands, 4N1K
significantly decreases stable adhesion of the SMC. At
submaximal densities of collagen and at all densities of
gelatin, this inhibition is as much as 50%. Thus, the effect
of 4N1K (and TSP1) on SMC chemotaxis, on gelatin, and
collagen (Wang and Frazier, 1998), may represent a case in
which loosening of tightly adherent cell contacts promotes
migration as pointed out by Dimilla et al. (1991) and
Lauffenburger and Horwitz (1996). This deadhesion effect
of 4N1K and TSP1 has been seen previously in C32 cells
adhering to vitronectin (Gao et al., 1996b), even though
stimulation of IAP in C32 cells causes enhanced cell
spreading which uses much the same cellular apparatus as
cell motility. Thus, it is not clear at this point just what the
state of the integrin is when it is activated via the IAP
pathway. By analogy with the platelet system, perhaps
a2b1 is in a state in which it binds soluble collagen better
(Shattil et al., 1994, 1998). Why this should result in de-
creased adhesion of cells to immobilized ligand is not obvi-
ous, but may relate to changes in the mobility or clustering
of the integrin on the cell surface (Lauffenburger and Hor-
witz, 1996).
IAP Stimulates Chemotaxis via a Heterotrimeric
Gi Protein
In platelets (Chung et al., 1997), C32 melanoma cells (Gao
et al., 1996a), and endothelial cells (Gao et al., 1996b),
IAP stimulates the activity of b3 integrins when ligated
with TSP1 or 4N1K peptide. This results in platelet aggre-
gation, C32 cell spreading, and endothelial cell chemo-
taxis. In all of these cases, the action of IAP is abrogated by
pertussis toxin treatment of the cells (Frazier et al., 1999).
Therefore, we tested the effect of pertussis toxin treatment
on the response of the SMC to 4N1K and collagen. Fig. 4
shows that treatment overnight with 50 ng/ml pertussis
toxin inhibited random migration to some extent, but com-
pletely eliminated the directional migration in response to
4N1K, collagen, or 4N1K plus collagen. Thus, the effects of
Figure 2. Activation of a2b1
results in enhanced chemo-
taxis. Human SMC were pre-
treated with 100 mM 4N1K,
4NGG, or 1:400 diluted anti-
a2b1 antibodies for 30 min at
378C before being added to
the wells. 5 mg/ml of col-
lagen-I was tested as chemo-
attractant.  a2b1-1 was a
function stimulating anti-
body, and a2b1-2 was a func-
tion blocking antibody. Data
are expressed as cells counted
per high power 6SD.
Figure 3. Adhesion of human SMC to collagen and gelatin. Hu-
man SMC were harvested as for chemotaxis assays and plated in
96-well plates coated with either collagen or gelatin at the indi-
cated concentrations. After incubation and washing, adherent
cells were quantified using a colorimetric assay as described
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IAP stimulation on a2b1 integrin function, like b3 inte-
grins, appear to be mediated via a heterotrimeric Gi pro-
tein.
Since IAP signaling is mediated via activation of Gi, the
alpha subunit of Gi might inhibit adenylate cyclase activity
(Neer, 1995). Thus, we examined the effect of IAP stimu-
lation on intracellular levels of cAMP in SMC. As seen in
Fig. 5 A, 4N1K alone evoked a rapid decrease in cAMP
levels to less than half their original value in 20 min while
the control peptide 4NGG had no significant effect. Inter-
estingly, soluble collagen alone caused a substantial but
transient decrease in cAMP levels while 4N1K plus col-
lagen, the most potent chemotactic stimulus, rapidly de-
creased intracellular cAMP to very low levels that did not
rebound by 40 min (Fig. 5 A). As seen in Fig. 5 B, pertussis
toxin pretreatment of the SMC increased control (prestim-
ulus) levels of cAMP as expected due to attenuation of in-
hibitory signals. The toxin also prevented the marked de-
crease in intracellular cAMP (at 40 min) caused by 4N1K
with or without collagen. These results strengthen the con-
clusion that, in SMC as in other cell types, IAP acts via Gi.
They also suggest that a decreased level of intracellular
cAMP may be necessary for the response.
To test this idea, SMC were treated with forskolin, a di-
rect activator of adenylate cyclase. As shown in Fig. 6, for-
skolin strongly inhibits the migration of SMC toward
4N1K or collagen alone and to 4N1K plus collagen. We
also tested the cell-permeable cAMP derivative 8-Br-
cAMP, and found that it also inhibited SMC chemotaxis to
all three stimuli (Fig. 6). Thus, 4N1K/IAP induces SMC
migration via activation of Gi, a necessary effect of which
is decreased cytoplasmic cyclic AMP levels.
4N1K Inhibits MAP Kinase/ERKs upon Activation
of Gi
In many cell types, integrin-mediated attachment of cells
to matrix proteins results in activation of MAP kinase p42/
44 or ERK (Chen et al., 1994; Shattil et al., 1994, 1998).
Furthermore, it has been reported (Klemke et al., 1997)
that ERK can regulate avb3-dependent haptotaxis of FG
carcinoma cells on vitronectin. Thus, we asked whether
IAP modulation of SMC chemotaxis might involve regula-
tion of ERKs. When SMC adhere to gelatin (or collagen,
not shown), they display a transient burst of ERK activity
that peaks z10 min after plating and then returns to base-
line levels (Fig. 7 A). 4N1K completely inhibited the in-
crease in MAP kinase activity at 10 min and continued to
decrease the baseline level of activity over time (Fig. 7 A).
The control peptide 4NGG had no effect (Fig. 7 A). West-
ern blotting using an antibody that detects the phosphory-
lated state of ERK confirmed this time course of activa-
tion (not shown). The inhibition of ERK activity appears
to be an active process since even the basal level of kinase
activity significantly declines over time with 4N1K treat-
ment even under conditions in which cells are actively en-
gaging the matrix (Fig. 7 A). To determine if engagement
of the integrin is required for IAP-mediated inhibition of
ERK activity, we harvested SMC and treated them with
4N1K in suspension. As seen in Fig. 7 B, the level of ERK
activity in suspended SMC is, as expected, somewhat
lower than in SMC attaching to collagen. Nonetheless,
Figure 4. Pertussis toxin in-
hibits chemotaxis. SMC were
treated with pertussis toxin
(PTX, 50 ng/ml) overnight in
serum-free medium, and har-
vested with EDTA/trypsin.
Cells were resuspended in
MEM with 0.1% BSA and 50
ng/ml of pertussis toxin, and
added directly to the chemo-
taxis chamber. Chemoattrac-
tants were as described in
Fig. 1. Data are expressed as
in Fig. 2.
Figure 5. 4N1K decreases intracellular cAMP levels and pertus-
sis toxin prevents the decrease in cAMP. (A) SMC were incu-
bated in suspension with 4N1K (100 mM), 4NGG (100 mM), solu-
ble collagen-I (5 mg/ml), or 4N1K plus collagen-I for the
indicated times at 378C. The cAMP assay was as described in Ma-
terials and Methods. (B) Cells were treated with pertussis toxin
(50 ng/ml) overnight and then incubated with 4N1K (100 mM), or
4N1K plus collagen-I (5 mg/ml) for 40 min in suspension. Data
are picomoles of cAMP 6SD.
Figure 6. Forskolin and 8-Br-cAMP inhibit SMC chemotaxis.
SMC were incubated with forskolin (FK, 24 mM) or 8-Br-cAMP
(100 mM) for 15 min before being added to the chemotaxis cham-
bers. Data are cell number 6SD.The Journal of Cell Biology, Volume 147, 1999 394
4N1K caused a significant inhibition of ERK activity in
suspended SMC while 4NGG had no effect. Significantly,
collagen had no effect on ERK activity under these condi-
tions, and collagen did not synergize with 4N1K to further
reduce ERK activity (Fig. 7 B). Since it is not clear to what
extent soluble collagen can bind to a2b1 under these con-
ditions, we also treated suspended SMC with the a2b1 in-
tegrin-activating mAb used above. Neither the mAb alone
nor in combination with a cross-linking anti–mouse IgG
had any effect on ERK activity. Thus, ligation of IAP
alone is sufficient to inhibit ERK activity and ligation and/
or cross-linking of a2b1 alone is not.
To test whether ERK in SMC can be regulated by Gi,
SMC were treated with pertussis toxin (50 ng/ml) over-
night. These same conditions lead to a blockade of IAP-
dependent chemotaxis (Fig. 4) and an increase in intracel-
lular cAMP levels (Fig. 5). The activation status of ERK
was then determined by MAP kinase immune complex ki-
nase assays. Fig. 8 shows that pertussis toxin treatment sig-
nificantly activates ERK in SMC, and the activation is con-
centration dependent. These results were confirmed by
Western blot using an antibody that detects the phos-
phorylated state of ERK (not shown). Thus, blockade of a
Gi-dependent pathway stimulates ERK activity indicating
that an inhibitory input has been attenuated, just as in the
elevation of intracellular cAMP levels by pertussis toxin
(Fig. 5 B). However, elevated cAMP does not cause the in-
crease in ERK activity. We find that treating SMC with
forskolin does not elevate ERK activity (our unpublished
data; Giasson et al., 1997).
Inhibition of ERKs Facilitates SMC Chemotaxis
Since 4N1K had a strong inhibitory effect on ERK activity,
the effect on chemotaxis of inhibiting ERK by other
means was tested. This was done in several ways. First,
SMC were treated with the MAP kinase kinase (MEK) in-
hibitor PD98059 resulting in a modest but significant stim-
ulation of chemotaxis to 4N1K and 4N1K plus soluble col-
lagen (Fig. 9). In another approach, we downregulated the
amount of ERK protein in SMC using an antisense oligo-
nucleotide based on the ERK mRNA sequence (Klemke
et al., 1997). Human SMC were treated with antisense and
control (scrambled) oligonucleotides in the presence of li-
pofectamine for 5 h followed by a 2-d recovery period
(Klemke et al., 1997). As shown in Fig. 10 A, treatment
with the antisense ERK oligonucleotide resulted in in-
creased migration to collagen, 4N1K, and 4N1K plus col-
lagen compared with cells treated with the scrambled
oligonucleotide. The same samples were subjected to
Western blot analysis with an anti-ERK antibody. As
shown in Fig. 10 B, the ERK protein levels were in fact
substantially decreased in cells treated with the antisense
ERK oligonucleotide (lane AS). ERK levels were the
same in untreated cells (Fig. 10 B, lane C) and in those
treated with lipofectamine and the control scrambled oli-
gonucleotide (lane SC).
As seen in Fig. 7 A, 4N1K causes a progressive decrease
Figure 7. 4N1K inhibits MAP kinase activa-
tion. (A) SMC were plated on gelatin- (100
mg/ml) coated dishes in the presence of 4N1K
or 4NGG (100 mM) for the indicated times,
and lysed in RIPA buffer. Cell lysates were
subjected to immunoprecipitation with anti-
ERK antibody. Kinase assays were per-
formed as described in Materials and Meth-
ods. Data are MAP kinase activity 6SD. (B)
SMC harvested as above were suspended in
buffered serum free culture medium and
treated indicated for 20 min when they were
harvested and processed for ERK activity as-
say as above. Treatments were: control, no
additions; 4NGG and 4N1K (100 mM); Col,
collagen at 5 mg/ml; 4N1K1Col, 100 mM and
5 mg/ml; a2b1, function-stimulating anti-a2b1
mAb was used at a 1:50 dilution of the com-
mercial preparation; mIgG, cross-linking anti–
mouse IgG was at 20 mg/ml;  a2b11mIgG,
both at the stated concentrations.
Figure 8. Pertussis toxin stimulates MAP kinase in SMC. SMC
were treated with pertussis toxin (PTX) at the concentrations in-
dicated overnight, and lysed directly in RIPA buffer. Cell lysates
were subjected to immunoprecipitation using anti-ERK anti-
body. Kinase assays were performed as described in Materials
and Methods. Data are MAP kinase activity 6SD.Wang et al. IAP Activates a2b1 via Regulation of cAMP and ERK 395
in ERK activity in SMC suggesting an active suppression
of ERK activity. This is normally accomplished in cells by
MAP kinase phosphatases which serve to balance and at-
tenuate the activation of MAP kinases (Keyse, 1998).
Thus, in a separate approach, we transiently transfected
SMC with plasmid 3CH134 encoding MAP kinase phos-
phatase-1 (MKP-1) which can dephosphorylate MAP ki-
nases activated by serum or v-raf (Sun et al., 1993). To de-
termine if the MKP-1 was active in the transfected SMC,
ERK activity was tested in cells replated on gelatin-coated
surfaces after the cells were recovered for 48 h. As shown
in Fig. 11 A, MAP kinase (primarily p42) phosphorylation
was increased when control cells were attached to a gela-
tin-coated surface for 10 min (control). By 30 min, phos-
phorylation had returned to near basal levels (as in Fig. 7).
Treatment with PMA (Fig. 11 A, right lane) sustained
phosphorylation through 30 min. Transfection with the
vector control (Fig. 11 A, VT) gave the same result as the
control. However, in cells expressing wild-type MKP-1
(WT), the attachment-induced increase in ERK phos-
phorylation at 10 min was essentially blocked. Interestingly,
in SMC transfected with the mutant MKP-1 in which the
essential catalytic cysteine is replaced (Sun et al., 1993),
phosphorylation of ERK is sustained through 30 min (Fig.
11 A, MT), indicating that MKPs likely play a normal role
in effecting the decrease in ERK phosphorylation in SMC.
The same transfected cells were also subjected to chemo-
taxis assays in which they were stimulated with soluble col-
lagen alone, 4N1K alone, or 4N1K plus collagen (Fig. 11
B). In the MKP-1–transfected cells, all three stimuli were
about twofold more effective chemoattractants than in the
vector control or mutant MKP1 transfected SMC. The mu-
tant MKP-1, which causes a prolonged activation of ERK
(Fig. 11 A), has the same chemotactic response as the con-
trol. Thus, it appears that the transient nature of ERK
phosphorylation may not be essential for the normal level
of chemotaxis. The significant result here is that when
ERK activation is attenuated, the chemotactic response to
all three stimuli is enhanced. Thus, three different meth-
ods of decreasing ERK activity all result in enhanced
chemotaxis toward collagen and magnify the effect of
4N1K.
Discussion
IAP is a widely distributed membrane protein implicated
in modulating integrin functions required for Ca21 fluxes
(Schwartz et al., 1993), phagocytosis (Blystone et al., 1995),
transendothelial (Cooper et al., 1995), and transepithelial
(Parkos et al., 1996) migration of PMNs, endothelial cell
migration (Gao et al., 1996a), as well as integrin-mediated
C32 cell spreading (Gao et al., 1996a) and platelet spread-
ing and aggregation (Chung et al., 1997, 1999). Many of
these functions involve modulation of b3 integrins. We
have shown that TSP1, through its IAP-binding motif, the
4N1K peptide, is able to modulate the activities associated
with the a2b1 integrin such that it can promote chemo-
taxis of human, rat (Wang and Frazier, 1998), and mouse
(this report) arterial SMC toward soluble collagen-I. This
effect of TSP1 and 4N1K on a2b1-mediated chemotaxis
requires IAP. Chemotaxis of IAP-deficient SMC toward
soluble collagen cannot be stimulated by 4N1K (Fig. 1)
even though these cells adhere to gelatin and collagen as
well as IAP1/1 control cells. These experiments represent
the most direct proof to date that TSPs, via the 4N1K pep-
tide, act through IAP to augment b1 integrin function.
How does this occur? The effect of 4N1K-IAP on a2b1-
dependent migration on gelatin can be conceptualized in
two different ways. First, IAP may alter the affinity state
of a2b1, either by direct physical interaction (Wang and
Frazier, 1998) or via inside out signaling. Our previous
data from platelets support such an affinity modulation
model. The ability of 4N1K (or TSP 1 or its recombinant
COOH-terminal domain, McDonald, J.F., X.-Q. Wang,
and W.A. Frazier, unpublished data) to enhance SMC
chemotaxis to soluble collagen is reminiscent of the activa-
tion of platelet aIIbb3 by 4N1K/TSP-1 (Chung et al., 1997,
1999). This effect in platelets is also dependent on IAP
since platelets from IAP deficient mice do not aggregate in
response to 4N1K or TSP 1 (Chung et al., 1999). The fact
that 4N1K pretreatment can stimulate migration to solu-
Figure 9. Effect of PD 98059
on SMC chemotaxis. SMC
were incubated with
PD98059 (PD, 50 nM) for 30
min at 378C before being
added to the chemotaxis
chambers. Chemoattractants
were as described above.
Data are cell number 6SD.
Figure 10. Anti-sense downregulation of ERK enhances SMC
chemotaxis. (A) Cell migration assay. Cell migration was tested
after ERK was depleted with anti-sense ERK oligonucleotide
(AS). Data are expressed as the percentage of increased cell mi-
gration above that of the scrambled oligonucleotide-treated cells
(SC). (B) Western blotting. The same cells tested in the migra-
tion assay in A were lysed in RIPA buffer, and after SDS PAGE,
blots were probed with anti-ERK antibody. Lane AS, treated
with anti-sense oligonucleotide; lane SC, treated with control oli-
gonucleotide; lane C, no treatment. Blots were stripped and
probed with an anti-actin antibody as a loading control.The Journal of Cell Biology, Volume 147, 1999 396
ble collagen is suggestive of a change in the activation sta-
tus of a2b1 that lasts long enough to be manifested during
the several hours required for cells to migrate through the
filters. An activating mAb against a2b1 gives the same re-
sult, i.e., enhanced chemotaxis to soluble collagen, which is
a poor ligand for the basal state of the integrin (Santoro
and Zutter, 1995) just as soluble fibrinogen is a terrible
ligand for aIIbb3 on quiescent platelets (Shattil et al.,
1994). Thus, the enhanced chemotaxis toward soluble col-
lagen by 4N1K may be analogous to the stimulation of
soluble fibrinogen binding to platelet aIIbb3 by 4N1K
(Chung et al., 1997, 1999) which leads to platelet aggrega-
tion. In platelets, the binding of the ligand mimetic mAb
PAC-1 can be used as an index of aIIbb3 affinity. In the
case of a2b1, there is no such convenient marker for a
higher affinity/avidity state of the unliganded integrin. The
effect of 4N1K to decrease cell adhesion as measured in a
static adhesion assay (Fig. 3) appears to argue against a
simple activation of ligand binding by the integrin, since
this would normally be expected to enhance not inhibit
cell adhesion. This result speaks to some change in the
state of the integrin’s valency or affinity, but the nature of
this change is unclear at the present time.
The second hypothesis, which need not be exclusive
with affinity modulation, is that IAP signaling is integrated
with a2b1 signaling at one or more levels inside the cell.
Both collagen and 4N1K lead to a drop in intracellular
cAMP levels. With collagen alone, this effect is transient,
whereas 4N1K leads to the sustained suppression of
cAMP which is enhanced by coadministration of collagen.
This effect is Gi dependent, as shown by experiments with
pertussis toxin, and independent of adhesion and integrin
engagement, as shown by experiments with suspended
cells. The decrease in cAMP levels and the inhibition of
ERK activity can both have profound effects on the cell’s
motility apparatus (Tan et al., 1992; Klemke et al., 1997),
and perhaps on other events upstream that connect inte-
grin engagement to cell motility.
The precipitous drop of cAMP levels in the SMC upon
treatment with 4N1K is likely to be due to a direct action
of Gia[GTP] on adenylate cyclase. In platelets and in leuko-
cytes, high levels of cAMP appear to block the transition
to a more active state of the integrins (Shattil et al., 1994,
1998; Laudanna et al., 1997). Thus, our observation that a
prominent effect of IAP stimulation in SMC is a profound
drop in intracellular cAMP levels may well be related to
removing a brake on a2b1 function. This effect is pertussis
toxin sensitive and thus clearly requires Gi function (Fig. 5
B). We have found an identical, IAP-dependent, pertussis
toxin-sensitive depletion of cAMP in platelets (Chung et al.,
1997; Frazier et al., 1999) where other costimulators of in-
tegrin activation such as thrombin, epinephrine, and ADP
act via G proteins to lower cAMP levels (Shattil et al.,
1994). Soluble collagen alone also causes a transient fall in
cAMP in SMC. Together, 4N1K and collagen synergize,
resulting in a more profound and prolonged decrease of
cAMP levels, in parallel with the more pronounced
chemotactic response elicited by the combined stimuli.
This suggests that the integrin and IAP work together to
activate Gi. In fact, we have recently found that 4N1K or
TSP1 ligation of IAP on platelets synergizes with collagen
ligation of a2b1 to induce platelet activation and aggrega-
tion (Chung et al., 1999). That a heterotrimeric complex of
integrin and IAP is the functional signaling unit is further
indicated by the existence of a detergent-stable integrin/
IAP complex in SMC (Wang and Frazier, 1998), in plate-
lets (Chung et al., 1999), and in melanoma cells which is
physically associated with Gi (Frazier et al., 1999). In addi-
tion, Gi can be copurified with IAP and its integrin partner
by affinity chromatography on immobilized 4N1K, and by
immunoprecipitation with anti-IAP mAbs. Furthermore,
4N1K stimulates the binding of g-[35S]GTP to cell mem-
branes and this stimulation requires IAP since it is not ob-
served in membranes from cells of IAP knockout mice
(Frazier et al., 1999). This result with isolated membranes
makes it unlikely that IAP signals the synthesis of an auto-
crine factor which then indirectly activates Gi through its
own Gi coupled serpentine receptor. If ligation of IAP is
required to activate Gi, how then does collagen alone
cause a decrease in cAMP levels (Fig. 5 A)? Our prelimi-
nary data suggests that cross-linking of the integrin-IAP
complex by collagen may responsible.
Another immediate result of IAP stimulation with
4N1K is a suppression of ERK activity and phosphoryla-
tion (Fig. 7). That this suppression of ERK activity is
causal for chemotaxis is indicated by the fact that three
Figure 11. Expression of MKP-1
in SMC enhances chemotaxis.
(A). Western blotting. After
transfection and recovery, cells
were plated on 100 mg/ml gelatin-
coated dishes for the indicated
times after which cells were lysed
in RIPA buffer, processed for
SDS PAGE, and blotted. The ac-
tivation of MAP kinase was de-
tected through Western blotting
with anti-activated MAP kinase
antibody. S, cells kept in suspen-
sion; Control, untransfected cells
attaching to collagen; MT, cells
transfected with inactive mutant MKP1; WT, cells transfected with wild-type MKP1; VT, vector control transfectants. PMA, cells in sus-
pension treated with 100 ng/ml PMA for 30 min. (B) Chemotaxis assay. The same cells were tested in the chemotaxis assay as above.
Data are expressed as the percentage of increased cell migration over no stimulus.Wang et al. IAP Activates a2b1 via Regulation of cAMP and ERK 397
different methods of inhibiting ERKs all result in en-
hanced chemotaxis (Figs. 9–11). A mechanism of integrin
modulation that involves ERKs is suggested by experi-
ments of Hughes et al. (1997) in which a chimeric integrin
expressed in CHO cells was engineered to be in an acti-
vated state as determined by the binding of the ligand-
mimetic mAb, PAC-1. Then cDNAs were expressed in the
CHO cells and screened for inhibition of PAC-1 binding.
Several inhibitory or integrin deactivating cDNAs were
identified and all encoded activators of the ERK pathway
such as activated H-ras and raf-1. These results suggest
that MAP kinase, specifically ERKs, inhibit integrin acti-
vation of the sort required for binding of soluble ligands.
Interestingly, it has been reported that activation of
aIIbb3 and binding of soluble fibrinogen to platelets co-
incides with inhibition of ERKs (Nadal et al., 1997).
Whether ERK inhibition might cause aIIbb3 activation
was not determined. We used three very different ways of
decreasing ERK activity and all three led to an increased
chemotactic response of SMC. The modulation of a2b1
activity in SMC by IAP suggested by our data may be the
first physiological example of the ERK regulation of inte-
grin affinity/avidity.
Klemke et al. (1997) have reported that a2b1-depen-
dent migration of FG carcinoma cells on a collagen sub-
strate required activation of MAPK/ERK. While their as-
say used a Boyden chamber apparatus like our chemotaxis
assays, the filters on which the cells migrated were coated
with fibronectin only on the bottom side. Their assay was
thus a haptotaxis assay which measures increased adhe-
sion to the matrix protein coated on the underside of the
filter. Thus, their result is that activation of ERKs results
in increased integrin-mediated adhesion to matrix, not in-
creased chemotaxis as observed here for SMC. In fact, we
observe (Fig. 3) that activation of IAP with 4N1K results
in decreased adhesion concomitant with increased chemo-
tactic migration. Importantly, Klemke et al. (1997) found
that inhibition of ERKs did not prevent spreading of the
FG cells, a cellular function closely allied to cell migration.
Thus, our results are, in fact, consistent with those of
Hughes et al. (1997) and Klemke et al. (1997), and rein-
force the idea that activation of MAPK/ERKs inhibits
binding of soluble ligands to integrins and also stimulates
integrin-mediated adhesion which can inhibit cell migra-
tion. The finding that ERKs can phosphorylate MLCK
(Klemke et al., 1997) may also support the second model
for IAP action to regulate cell motility at downstream
sites.
The mechanism by which IAP inhibits ERK activity is
not clear. We find that ERK activity is stimulated by dis-
abling Gi with pertussis toxin (Fig. 8) suggesting that un-
der normal growth conditions, some tonic input acts
through Gi to exert a negative influence on ERK activity
in SMC. This negative regulation may be due to bg since
expression in SMC of the b-ARK COOH-terminal do-
main that sequesters bg also stimulates ERK activity in
randomly cycling, proliferating cultures of SMC (Wang,
X.-Q., and W.A. Frazier, unpublished data). This result is
in contrast to recently published data on the role of bg as a
positive effector of ERK activation in serum-starved SMC
stimulated with serum or growth factors (Iaccarino et al.,
1999). However, the effects of bg sequestration are poten-
tially quite complex, impacting not only downstream tar-
gets of bg, but also receptor desensitization and down reg-
ulation (Lefkowitz, 1998). Thus, it is conceivable that bg
sequestration may differ in its net result when tested in
proliferating vs synchronized cells stimulated to enter the
cell cycle.
Whatever the mechanism, the essential role of a Gi pro-
tein in the stimulation of chemotaxis by 4N1K is clearly
demonstrated by the effect of pertussis toxin treatment of
the SMC. The downstream events that lead to the effects
on cell motility that we observe could be mediated by the
Gia subunit or the bg heterodimer released upon activa-
tion and dissociation of Gi (Hawes et al., 1995; Neer,
1995). The inhibition of chemotaxis by forskolin and 8-Br-
cAMP implies that decreased cAMP (and lower PKA ac-
tivity) is necessary to allow directed migration (Fig. 6).
This observation is consistent with other studies of SMC
chemotaxis (Dubey et al., 1995; Palmer et al., 1998) and
with the inhibitory effect of high cAMP levels on activa-
tion of leukocyte integrins (Laudanna et al., 1997) and the
long known inhibitory effect of cAMP on activation of the
platelet integrin aIIbb3 (Shattil et al., 1994). Another well
known effect of cAMP is the PKA-mediated inhibition of
cell motility via phosphorylation of myosin light chain
(Tan et al., 1992) which would also put a brake on chemo-
taxis until cAMP levels are reduced.
It has been reported (Graves et al., 1996) that adenylate
cyclase is downstream of MAP kinase in SMC, since acti-
vated ERKs can increase cAMP levels. This occurs via
ERK-mediated phosphorylation and activation of PLA2
leading to prostaglandin production, and autocrine ade-
nylate cyclase stimulation via Gs (Graves et al., 1996). In
addition to 4N1K, PD98059 also decreases cAMP levels in
SMC (our unpublished data). Thus, when ERK is in-
hibited, cAMP levels follow. However, manipulation of
cAMP levels does not appear to affect ERK (our unpub-
lished data; Giasson et al., 1997), consistent with the idea
that ERK regulation is upstream of adenylate cyclase in
SMC (Graves et al., 1996). Thus, activation of Gi can
lower cAMP levels in two ways: direct inhibition of ade-
nylate cyclase by Gia and inhibition of ERKs leading to
decreased stimulation of cyclase via the prostaglandin
pathway. It appears that both decreased cyclic AMP levels
and lower ERK activity are necessary for IAP modulation
of SMC motility.
The data reported here indicate a novel role for TSP
family members (all of which contain the IAP binding se-
quence) and IAP in the regulation of SMC migration. This
may occur via modulation of a b1 integrin mediated by in-
hibition of MAP kinase, and a concomitant decrease in in-
tracellular cyclic AMP levels. Both of these signaling
events are tremendously pleiotropic, and both PKA and
ERKs have been shown to impact regulation of cell motil-
ity via direct phosphorylation of myosin light chain kinase
and/or myosin light chain (Tan et al., 1992; Klemke et al.,
1997). Thus, IAP may act at multiple levels to modulate
integrin function as well as facilitating signaling down-
stream of integrin ligation. There is ample literature impli-
cating TSP1 in the proliferation and chemotaxis of cul-
tured SMC (Majack et al., 1986, 1988; Yabkowitz et al.,
1993; Patel et al., 1997; Wang and Frazier, 1998) and in
atherogenesis (Wight et al., 1985) and restenosis (Chen et al.,The Journal of Cell Biology, Volume 147, 1999 398
1999). Our data suggest the possibility that manipulation
of TSP1 signaling through IAP may be of therapeutic ben-
efit.
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